Stopping sales before the deadline may not be enough—existing claims‑made policies still expose firms to prior‑products liability.
The federal hemp definition changes on December 11 2026, shifting the THC limit from delta‑9 alone to total THC, including THCA, per P.L. 119‑37, with most provisions delayed by P.L. 119‑103.
Products that currently meet the delta‑9 or delta‑8 thresholds will fail the new total‑THC standard, and insurers have not yet settled how they will treat existing coverage.
“The insurance policy doesn’t necessarily just go away, but now we have to understand how the carrier will treat that product,” said Lee Woodruff, Jencap’s cannabis vice‑president.
Legal manufacturers and sellers whose products remain on shelves or in consumers’ hands after December 11 create coverage uncertainty, especially when injury claims arise later.
Jencap is extending some policies to December 31 2026 instead of standard 12‑month renewals to buy time while the market adjusts.
Coverage doesn’t go away, but it’s not guaranteed either
“The insurance policy doesn’t necessarily just go away, but now we have to understand how the carrier is going to treat that product,” Woodruff said. The rule leaves several unresolved scenarios, such as products already sold or in consumer hands.
The prior‑products gap most operators will miss
Even if a company stops selling a product before December 11, claims‑made liability coverage still applies to injuries from products that were manufactured and sold earlier.
Because claims arise after the sale, brokers must discuss tail coverage or discontinued‑products coverage to protect prior exposure.
Policy language that needs immediate review
Brokers should scrutinize how hemp, cannabis, THC, and cannabinoids are defined, examine exclusions for controlled substances, assess compliance language tied to federal or state law, consider vape and inhalation exclusions, review scheduled product clauses, and verify tail coverage, reporting requirements, and defense‑cost provisions.
Three questions every broker should be asking carriers now
First, brokers need a clear picture of what each client presently sells, including which products are being discontinued, reformulated, or retained, and what inventory sits in warehouses.
Does the carrier consider the products the insured will continue selling after the rule change as acceptable and covered?
How will the carrier handle claims from products legally manufactured and sold before the change if a consumer later alleges injury?
What protection is in place for claims on products the insured has stopped selling, and is tail coverage or another solution required?
Assuming existing coverage will handle everything creates greater risk than engaging the carrier now, even if the answer is still pending.
